Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ryan Bruce Corcoran, M.D.

Title
Institution
Department
Address

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. U54CA224068 (CORCORAN, RYAN BRUCE) Sep 30, 2017 - Aug 31, 2022
    NIH
    An integrated translational approach to overcome drug resistance
    Role: Principal Investigator
  2. R01CA208437 (CORCORAN, RYAN BRUCE) Jul 1, 2016 - Jun 30, 2021
    NIH
    Therapeutic resistance and tumor heterogeneity in BRAF mutant colorectal cancer
    Role: Principal Investigator
  3. K08CA166510 (CORCORAN, RYAN BRUCE) Dec 18, 2012 - Nov 30, 2017
    NIH
    Combination Therapy to Improve MAPK Pathway Inhibitor Efficacy in BRAF and KRAS M
    Role: Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Tian J, Chen JH, Chao SX, Pelka K, Giannakis M, Hess J, Burke K, Jorgji V, Sindurakar P, Braverman J, Mehta A, Oka T, Huang M, Lieb D, Spurrell M, Allen JN, Abrams TA, Clark JW, Enzinger AC, Enzinger PC, Klempner SJ, McCleary NJ, Meyerhardt JA, Ryan DP, Yurgelun MB, Kanter K, Van Seventer EE, Baiev I, Chi G, Jarnagin J, Bradford WB, Wong E, Michel AG, Fetter IJ, Siravegna G, Gemma AJ, Sharpe A, Demehri S, Leary R, Campbell CD, Yilmaz O, Getz GA, Parikh AR, Hacohen N, Corcoran RB. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nat Med. 2023 02; 29(2):458-466. PMID: 36702949; PMCID: PMC9941044.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  2. Sun Y, Revach OY, Anderson S, Kessler EA, Wolfe CH, Jenney A, Mills CE, Robitschek EJ, Davis TGR, Kim S, Fu A, Ma X, Gwee J, Tiwari P, Du PP, Sindurakar P, Tian J, Mehta A, Schneider AM, Yizhak K, Sade-Feldman M, LaSalle T, Sharova T, Xie H, Liu S, Michaud WA, Saad-Beretta R, Yates KB, Iracheta-Vellve A, Spetz JKE, Qin X, Sarosiek KA, Zhang G, Kim JW, Su MY, Cicerchia AM, Rasmussen MQ, Klempner SJ, Juric D, Pai SI, Miller DM, Giobbie-Hurder A, Chen JH, Pelka K, Frederick DT, Stinson S, Ivanova E, Aref AR, Paweletz CP, Barbie DA, Sen DR, Fisher DE, Corcoran RB, Hacohen N, Sorger PK, Flaherty KT, Boland GM, Manguso RT, Jenkins RW. Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature. 2023 Mar; 615(7950):158-167. PMID: 36634707.
    Citations:    Fields:    Translation:Humans
  3. Corcoran RB. Line by Line: Distinct Patterns of Anti-EGFR Antibody Resistance by Line of Therapy. J Clin Oncol. 2023 Jan 20; 41(3):436-438. PMID: 36480767.
    Citations:    Fields:    Translation:HumansCells
  4. Sanidas I, Lee H, Rumde PH, Boulay G, Morris R, Golczer G, Stanzione M, Hajizadeh S, Zhong J, Ryan MB, Corcoran RB, Drapkin BJ, Rivera MN, Dyson NJ, Lawrence MS. Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression. Mol Cell. 2022 09 15; 82(18):3333-3349.e9. PMID: 35981542; PMCID: PMC9481721.
    Citations: 2     Fields:    Translation:Cells
  5. Ryan MB, Coker O, Sorokin A, Fella K, Barnes H, Wong E, Kanikarla P, Gao F, Zhang Y, Zhou L, Kopetz S, Corcoran RB. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep. 2022 06 21; 39(12):110993. PMID: 35732135; PMCID: PMC9809542.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  6. Rajurkar M, Parikh AR, Solovyov A, You E, Kulkarni AS, Chu C, Xu KH, Jaicks C, Taylor MS, Wu C, Alexander KA, Good CR, Szabolcs A, Gerstberger S, Tran AV, Xu N, Ebright RY, Van Seventer EE, Vo KD, Tai EC, Lu C, Joseph-Chazan J, Raabe MJ, Nieman LT, Desai N, Arora KS, Ligorio M, Thapar V, Cohen L, Garden PM, Senussi Y, Zheng H, Allen JN, Blaszkowsky LS, Clark JW, Goyal L, Wo JY, Ryan DP, Corcoran RB, Deshpande V, Rivera MN, Aryee MJ, Hong TS, Berger SL, Walt DR, Burns KH, Park PJ, Greenbaum BD, Ting DT. Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. Cancer Discov. 2022 06 02; 12(6):1462-1481. PMID: 35320348; PMCID: PMC9167735.
    Citations: 6     Fields:    Translation:HumansAnimals
  7. Siravegna G, O'Boyle CJ, Varmeh S, Queenan N, Michel A, Stein J, Thierauf J, Sadow PM, Faquin WC, Perry SK, Bard AZ, Wang W, Deschler DG, Emerick KS, Varvares MA, Park JC, Clark JR, Chan AW, Andreu Arasa VC, Sakai O, Lennerz J, Corcoran RB, Wirth LJ, Lin DT, Iafrate AJ, Richmon JD, Faden DL. Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer. Clin Cancer Res. 2022 02 15; 28(4):719-727. PMID: 34857594; PMCID: PMC8866203.
    Citations: 3     Fields:    Translation:HumansCells
  8. O'Boyle CJ, Siravegna G, Varmeh S, Queenan N, Michel A, Pang KCS, Stein J, Thierauf JC, Sadow PM, Faquin WC, Wang W, Deschler DG, Emerick KS, Varvares MA, Park JC, Clark JR, Chan AW, Busse PM, Corcoran RB, Wirth LJ, Lin DT, Iafrate AJ, Richmon JD, Faden DL. Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer. Cancer. 2022 06 01; 128(11):2193-2204. PMID: 35139236; PMCID: PMC10032347.
    Citations: 7     Fields:    Translation:HumansCells
  9. Parikh AR, Corcoran RB. Plasma-only ctDNA-Guided MRD Detection in Patients with CRC-Response. Clin Cancer Res. 2021 12 01; 27(23):6614-6615. PMID: 34853075; PMCID: PMC9762546.
    Citations: 1     Fields:    Translation:Humans
  10. Parikh AR, Szabolcs A, Allen JN, Clark JW, Wo JY, Raabe M, Thel H, Hoyos D, Mehta A, Arshad S, Lieb DJ, Drapek LC, Blaszkowsky LS, Giantonio BJ, Weekes CD, Zhu AX, Goyal L, Nipp RD, Dubois JS, Van Seventer EE, Foreman BE, Matlack LE, Ly L, Meurer JA, Hacohen N, Ryan DP, Yeap BY, Corcoran RB, Greenbaum BD, Ting DT, Hong TS. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer. 2021 11; 2(11):1124-1135. PMID: 35122060; PMCID: PMC8809884.
    Citations: 20     Translation:HumansCellsCTClinical Trials
  11. Pelka K, Hofree M, Chen JH, Sarkizova S, Pirl JD, Jorgji V, Bejnood A, Dionne D, Ge WH, Xu KH, Chao SX, Zollinger DR, Lieb DJ, Reeves JW, Fuhrman CA, Hoang ML, Delorey T, Nguyen LT, Waldman J, Klapholz M, Wakiro I, Cohen O, Albers J, Smillie CS, Cuoco MS, Wu J, Su MJ, Yeung J, Vijaykumar B, Magnuson AM, Asinovski N, Moll T, Goder-Reiser MN, Applebaum AS, Brais LK, DelloStritto LK, Denning SL, Phillips ST, Hill EK, Meehan JK, Frederick DT, Sharova T, Kanodia A, Todres EZ, Jané-Valbuena J, Biton M, Izar B, Lambden CD, Clancy TE, Bleday R, Melnitchouk N, Irani J, Kunitake H, Berger DL, Srivastava A, Hornick JL, Ogino S, Rotem A, Vigneau S, Johnson BE, Corcoran RB, Sharpe AH, Kuchroo VK, Ng K, Giannakis M, Nieman LT, Boland GM, Aguirre AJ, Anderson AC, Rozenblatt-Rosen O, Regev A, Hacohen N. Spatially organized multicellular immune hubs in human colorectal cancer. Cell. 2021 09 02; 184(18):4734-4752.e20. PMID: 34450029; PMCID: PMC8772395.
    Citations: 54     Fields:    Translation:HumansCells
  12. Wo JY, Clark JW, Eyler CE, Mino-Kenudson M, Klempner SJ, Allen JN, Keane FK, Parikh AR, Roeland E, Drapek LC, Ryan DP, Corcoran RB, Van Seventer E, Fetter IJ, Shahzade HA, Khandekar MJ, Lanuti M, Morse CR, Heist RS, Ulysse CA, Christopher B, Baglini C, Yeap BY, Mullen JT, Hong TS. Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clin Cancer Res. 2021 12 01; 27(23):6343-6353. PMID: 34330715.
    Citations: 2     Fields:    Translation:Humans
  13. Kanter K, Fish M, Mauri G, Horick NK, Allen JN, Blaszkowsky LS, Clark JW, Ryan DP, Nipp RD, Giantonio BJ, Goyal L, Dubois J, Murphy JE, Franses J, Klempner SJ, Roeland EJ, Weekes CD, Wo JY, Hong TS, Van Seventer EE, Corcoran RB, Parikh AR. Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer. JCO Oncol Pract. 2021 12; 17(12):e1846-e1855. PMID: 34043449.
    Citations: 3     Fields:    Translation:Humans
  14. Best TD, Roeland EJ, Horick NK, Van Seventer EE, El-Jawahri A, Troschel AS, Johnson PC, Kanter KN, Fish MG, Marquardt JP, Bridge CP, Temel JS, Corcoran RB, Nipp RD, Fintelmann FJ. Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss. Oncologist. 2021 06; 26(6):e963-e970. PMID: 33818860.
    Citations: 1     Fields:    Translation:Humans
  15. Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta HV, Rubinson DA, Fetter IJ, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais LK, Loftus M, Shinagare AB, Abrams TA, Clancy TE, Wang J, Patel AK, Brichory F, Vaslin Chessex A, Sullivan RJ, Keller RB, Denning S, Hill ER, Shapiro GI, Pokorska-Bocci A, Zanna C, Ng K, Schrag D, Jänne PA, Hahn WC, Cherniack AD, Corcoran RB, Meyerson M, Daina A, Zoete V, Bardeesy N, Wolpin BM. FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 10; 11(10):2488-2505. PMID: 33926920; PMCID: PMC8690974.
    Citations: 10     Fields:    Translation:Humans
  16. Parikh AR, Van Seventer EE, Siravegna G, Hartwig AV, Jaimovich A, He Y, Kanter K, Fish MG, Fosbenner KD, Miao B, Phillips S, Carmichael JH, Sharma N, Jarnagin J, Baiev I, Shah YS, Fetter IJ, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Dubois JS, Franses JW, Giantonio BJ, Goyal L, Klempner SJ, Nipp RD, Roeland EJ, Ryan DP, Weekes CD, Wo JY, Hong TS, Bordeianou L, Ferrone CR, Qadan M, Kunitake H, Berger D, Ricciardi R, Cusack JC, Raymond VM, Talasaz A, Boland GM, Corcoran RB. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. 2021 10 15; 27(20):5586-5594. PMID: 33926918; PMCID: PMC8530842.
    Citations: 48     Fields:    Translation:Humans
  17. Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, Baiev I, Juric D, Gainor JF, Klempner SJ, Lennerz JK, Siravegna G, Bar-Peled L, Hata AN, Heist RS, Corcoran RB. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. Cancer Discov. 2021 08; 11(8):1913-1922. PMID: 33824136; PMCID: PMC8338755.
    Citations: 91     Fields:    Translation:Humans
  18. McDuff SGR, Hardiman KM, Ulintz PJ, Parikh AR, Zheng H, Kim DW, Lennerz JK, Hazar-Rethinam M, Van Seventer EE, Fetter IJ, Nadres B, Eyler CE, Ryan DP, Weekes CD, Clark JW, Cusack JC, Goyal L, Zhu AX, Wo JY, Blaszkowsky LS, Allen J, Corcoran RB, Hong TS. Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. JCO Precis Oncol. 2021; 5. PMID: 34250394; PMCID: PMC8232395.
    Citations: 10     Fields:    Translation:Humans
  19. Corcoran RB. Liquid biopsy versus tumor biopsy for clinical-trial recruitment. Nat Med. 2020 12; 26(12):1815-1816. PMID: 33230339.
    Citations: 12     Fields:    Translation:Humans
  20. van Seventer EE, Fish MG, Fosbenner K, Kanter K, Mojtahed A, Allen JN, Blaszkowsky L, Clark JW, Dubois J, Franses JW, Giantonio BJ, Goyal L, Klempner SJ, Roeland EJ, Ryan DP, Weekes CD, Mulvey T, El-Jawahri A, Horick N, Corcoran RB, Parikh AR, Nipp RD. Associations of baseline patient-reported outcomes with treatment outcomes in advanced gastrointestinal cancer. Cancer. 2021 02 15; 127(4):619-627. PMID: 33170962.
    Citations: 2     Fields:    Translation:Humans
  21. Velimirovic M, Juric D, Niemierko A, Spring L, Vidula N, Wander SA, Medford A, Parikh A, Malvarosa G, Yuen M, Corcoran R, Moy B, Isakoff SJ, Ellisen LW, Iafrate A, Chabner B, Bardia A. Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precis Oncol. 2020 Nov; 4:1246-1262. PMID: 35050782.
    Citations: 4     Fields:    
  22. Negreros-Osuna AA, Parakh A, Corcoran RB, Pourvaziri A, Kambadakone A, Ryan DP, Sahani DV. Radiomics Texture Features in Advanced Colorectal Cancer: Correlation with BRAF Mutation and 5-year Overall Survival. Radiol Imaging Cancer. 2020 09; 2(5):e190084. PMID: 33778733.
    Citations: 11     Fields:    Translation:Humans
  23. Chaudhary SP, Kwak EL, Hwang KL, Lennerz JK, Corcoran RB, Heist RS, Russo AL, Parikh A, Borger DR, Blaszkowsky LS, Faris JE, Murphy JE, Azzoli CG, Roeland EJ, Goyal L, Allen J, Mullen JT, Ryan DP, Iafrate AJ, Klempner SJ, Clark JW, Hong TS. Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers. Oncologist. 2020 11; 25(11):e1691-e1700. PMID: 32820577; PMCID: PMC7648344.
    Citations: 1     Fields:    Translation:Humans
  24. Lin JJ, Langenbucher A, Gupta P, Yoda S, Fetter IJ, Rooney M, Do A, Kem M, Chang KP, Oh AY, Chin E, Juric D, Corcoran RB, Dagogo-Jack I, Gainor JF, Stone JR, Lennerz JK, Lawrence MS, Hata AN, Mino-Kenudson M, Shaw AT. Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. NPJ Precis Oncol. 2020; 4:21. PMID: 32802958.
    Citations: 14     
  25. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020 12; 17(12):757-770. PMID: 32632268; PMCID: PMC7790747.
    Citations: 85     Fields:    Translation:Humans
  26. Jalili P, Bowen D, Langenbucher A, Park S, Aguirre K, Corcoran RB, Fleischman AG, Lawrence MS, Zou L, Buisson R. Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots. Nat Commun. 2020 06 12; 11(1):2971. PMID: 32532990.
    Citations: 28     Fields:    Translation:HumansCells
  27. Corcoran RB, Grothey A. Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer-Fact or Fiction? JAMA Oncol. 2020 06 01; 6(6):823-824. PMID: 32379270.
    Citations: 6     Fields:    Translation:HumansCells
  28. Gumusay O, Vitiello PP, Wabl C, Corcoran RB, Bardelli A, Rugo HS. Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. Am Soc Clin Oncol Educ Book. 2020 May; 40:e292-e308. PMID: 32453634.
    Citations: 1     Fields:    Translation:Humans
  29. Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, De Vos F, Van Cutsem E, Millholland JM, Brase JC, Rangwala F, Gasal E, Corcoran RB. BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clin Cancer Res. 2020 06 01; 26(11):2466-2476. PMID: 32047001.
    Citations: 11     Fields:    Translation:Humans
  30. Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, Sepulveda S, Wan L, Joseph R, Minogue E, Khatri A, Bardia A, Ellisen LW, Corcoran RB, Hata AN, Pai SI, Jain RK, Fukumura D, Duda DG, Cobbold M. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol. 2020 04; 38(4):420-425. PMID: 32042168.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  31. Parikh AR, Mojtahed A, Schneider JL, Kanter K, Van Seventer EE, Fetter IJ, Thabet A, Fish MG, Teshome B, Fosbenner K, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Ryan DP, Giantonio B, Goyal L, Nipp RD, Roeland E, Weekes CD, Wo JY, Zhu AX, Dias-Santagata D, Iafrate AJ, Lennerz JK, Hong TS, Siravegna G, Horick N, Clark JW, Corcoran RB. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res. 2020 04 15; 26(8):1877-1885. PMID: 31941831.
    Citations: 27     Fields:    Translation:Humans
  32. Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A. How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019 Oct; 30(10):1580-1590. PMID: 31987449.
    Citations:    
  33. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019 Feb; 30(2):243-249. PMID: 31987421.
    Citations:    
  34. Parikh A, Clark J, Wo J, Yeap B, Allen J, Blaszkowsky L, Ryan D, Giantonio B, Weekes C, Zhu A, Van Seventer E, Ly L, Matlack L, Foreman B, Drapek L, Ting D, Corcoran R, Hong T. Proof of concept of the abscopal effect in MSS GI cancers: A phase 2 study of ipilimumab and nivolumab with radiation in metastatic pancreatic and colorectal adenocarcinoma. Ann Oncol. 2019 Jul; 30 Suppl 4:iv128. PMID: 32085022.
    Citations:    
  35. Mauri G, Kanter K, Fish M, Horick N, Allen J, Blaszkowsky L, Clark J, Ryan D, Nipp R, Giantonio B, Goyal L, Dubois J, Murphy J, Roeland E, Weekes C, Wo J, Hong T, Zhu A, Van Seventer E, Corcoran R, Parikh A. PARP-ness in metastatic colorectal cancer. Ann Oncol. 2019 Jul; 30 Suppl 4:iv117. PMID: 32084989.
    Citations:    
  36. Parikh A, Van Seventer E, Boland G, Boland G, Hartwig A, Jaimovich A, Raymond V, Talasaz A, Corcoran R. Serial assessment of cell-free circulating tumor DNA (ctDNA) to assess treatment effect and minimal residual disease during neoadjuvant and adjuvant therapy in colorectal cancer. Ann Oncol. 2019 Jul; 30 Suppl 4:iv131. PMID: 32085033.
    Citations:    
  37. Parikh A, Kanter K, Mojtahed A, Schneider J, Van Seventer E, Fish M, Allen J, Blaszkowsky L, Wo J, Clark J, Giantonio B, Goyal L, Hong T, Nipp R, Roeland E, Weekes C, Zhu A, Ryan D, Fetter I, Horick N, Corcoran R. Serial circulating tumor DNA (ctDNA) monitoring to predict response to treatment in metastatic gastrointestinal cancers. Ann Oncol. 2019 Jul; 30 Suppl 4:iv112. PMID: 32084975.
    Citations:    
  38. Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, Danysh BP, de la Cruz FF, Fetter IJ, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Giantonio B, Murphy JE, Nipp RD, Roeland E, Ryan DP, Weekes CD, Kwak EL, Faris JE, Wo JY, Aguet F, Dey-Guha I, Hazar-Rethinam M, Dias-Santagata D, Ting DT, Zhu AX, Hong TS, Golub TR, Iafrate AJ, Adalsteinsson VA, Bardelli A, Parida L, Juric D, Getz G, Corcoran RB. Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 Dec; 25(12):1949. PMID: 31745334.
    Citations:    Fields:    
  39. Ryan MB, Fece de la Cruz F, Phat S, Myers DT, Wong E, Shahzade HA, Hong CB, Corcoran RB. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition. Clin Cancer Res. 2020 04 01; 26(7):1633-1643. PMID: 31776128; PMCID: PMC7124991.
    Citations: 121     Fields:    Translation:Humans
  40. Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A. How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019 10 01; 30(10):1580-1590. PMID: 31373349.
    Citations: 110     Fields:    Translation:Humans
  41. Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clin Cancer Res. 2020 01 15; 26(2):439-449. PMID: 31548343; PMCID: PMC6980768.
    Citations: 33     Fields:    Translation:HumansAnimalsCells
  42. Yaeger R, Kotani D, Mondaca S, Parikh AR, Bando H, Van Seventer EE, Taniguchi H, Zhao H, Thant CN, de Stanchina E, Rosen N, Corcoran RB, Yoshino T, Yao Z, Ebi H. Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer. Clin Cancer Res. 2019 12 01; 25(23):7089-7097. PMID: 31515458; PMCID: PMC6891165.
    Citations: 31     Fields:    Translation:HumansAnimalsCells
  43. Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, Danysh BP, de la Cruz FF, Fetter IJ, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Giantonio B, Murphy JE, Nipp RD, Roeland E, Ryan DP, Weekes CD, Kwak EL, Faris JE, Wo JY, Aguet F, Dey-Guha I, Hazar-Rethinam M, Dias-Santagata D, Ting DT, Zhu AX, Hong TS, Golub TR, Iafrate AJ, Adalsteinsson VA, Bardelli A, Parida L, Juric D, Getz G, Corcoran RB. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019 09; 25(9):1415-1421. PMID: 31501609; PMCID: PMC6741444.
    Citations: 157     Fields:    Translation:Humans
  44. Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jul 01; 5(7):1020-1027. PMID: 31145418; PMCID: PMC6547247.
    Citations: 167     Fields:    Translation:HumansCTClinical Trials
  45. Kamran SC, Lennerz JK, Margolis CA, Liu D, Reardon B, Wankowicz SA, Van Seventer EE, Tracy A, Wo JY, Carter SL, Willers H, Corcoran RB, Hong TS, Van Allen EM. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clin Cancer Res. 2019 09 15; 25(18):5561-5571. PMID: 31253631; PMCID: PMC6744983.
    Citations: 31     Fields:    Translation:HumansCells
  46. Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Cancer Discov. 2019 08; 9(8):1064-1079. PMID: 31109923; PMCID: PMC6677584.
    Citations: 108     Fields:    Translation:HumansCells
  47. Lieu CH, Corcoran RB, Overman MJ. Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:207-215. PMID: 31099678.
    Citations: 11     Fields:    Translation:Humans
  48. Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Oncologist. 2019 10; 24(10):1340-1347. PMID: 31040255.
    Citations: 40     Fields:    Translation:Humans
  49. Yaeger R, Corcoran RB. Targeting Alterations in the RAF-MEK Pathway. Cancer Discov. 2019 03; 9(3):329-341. PMID: 30770389; PMCID: PMC6397699.
    Citations: 136     Fields:    Translation:HumansAnimalsCells
  50. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019 02 01; 30(2):243-249. PMID: 30462160; PMCID: PMC6657008.
    Citations: 73     Fields:    Translation:HumansCells
  51. Corcoran RB, Chabner BA. Cell-free DNA Analysis in Cancer. N Engl J Med. 2019 01 31; 380(5):501-502. PMID: 30699310.
    Citations: 5     Fields:    Translation:Humans
  52. Corcoran RB, Chabner BA. Application of Cell-free DNA Analysis to Cancer Treatment. N Engl J Med. 2018 Nov 01; 379(18):1754-1765. PMID: 30380390.
    Citations: 260     Fields:    Translation:Humans
  53. Ryan MB, Corcoran RB. Therapeutic strategies to target RAS-mutant cancers. Nat Rev Clin Oncol. 2018 11; 15(11):709-720. PMID: 30275515.
    Citations: 122     Fields:    Translation:HumansCells
  54. Mitra D, Clark JW, Shih HA, Oh KS, Brastianos PK, Wo JY, Strickland MR, Curry WT, Parikh AR, Corcoran RB, Ryan DP, Iafrate AJ, Borger DR, Lennerz JK, Hong TS. Enrichment of HER2 Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. Oncologist. 2019 02; 24(2):193-201. PMID: 30373904; PMCID: PMC6369954.
    Citations: 7     Fields:    Translation:Humans
  55. Siravegna G, Corcoran RB. Blood-Based Prediction of Tumor Relapse: The cfDNA Forecast. Cancer Discov. 2018 10; 8(10):1213-1215. PMID: 30279194.
    Citations: 1     Fields:    Translation:Humans
  56. Piotrowska Z, Hazar-Rethinam M, Rizzo C, Nadres B, Van Seventer EE, Shahzade HA, Lennes IT, Iafrate AJ, Dias-Santagata D, Leshchiner I, Jessop NA, Hu H, Digumarthy SR, Nagy RJ, Lanman RB, Moody S, Niederst MJ, Engelman JA, Hata AN, Corcoran RB, Sequist LV. Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. JCO Precis Oncol. 2018; 2018. PMID: 30123863; PMCID: PMC6097183.
    Citations: 7     Fields:    
  57. Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy T, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shapiro GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Carter SL, Wolpin BM. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111. PMID: 29903880.
    Citations: 134     Fields:    Translation:HumansCells
  58. Fece de la Cruz F, Corcoran RB. Methylation in cell-free DNA for early cancer detection. Ann Oncol. 2018 06 01; 29(6):1351-1353. PMID: 29668834.
    Citations: 13     Fields:    Translation:HumansCells
  59. Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS. Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Med. 2018 Jul; 7(7):2934-2942. PMID: 29771009; PMCID: PMC6051212.
    Citations: 12     Fields:    
  60. Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discov. 2018 04; 8(4):428-443. PMID: 29431699.
    Citations: 204     Fields:    Translation:HumansCellsCTClinical Trials
  61. Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, Nadres B, Hong CB, Gurski JM, Jessop NA, Dias-Santagata D, Iafrate AJ, Van Allen EM, Corcoran RB. Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer. Cancer Discov. 2018 04; 8(4):417-427. PMID: 29431697; PMCID: PMC5882515.
    Citations: 26     Fields:    Translation:HumansAnimalsCells
  62. Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Oncoimmunology. 2018; 7(5):e1423172. PMID: 29721378.
    Citations: 12     Fields:    
  63. Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran RB, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018 04 01; 36(10):1020-1044. PMID: 29380678.
    Citations: 46     Fields:    Translation:Humans
  64. Parikh AR, Corcoran RB. Monitoring resistance through liquid biopsy. Ann Oncol. 2018 01 01; 29(1):8-11. PMID: 29087449; PMCID: PMC6658708.
    Citations: 4     Fields:    Translation:Humans
  65. Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S. Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discov. 2018 02; 8(2):164-173. PMID: 29196463.
    Citations: 114     Fields:    Translation:Humans
  66. Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum H, Blackmon SM, Frederick DT, Hazar-Rethinam M, Nadres BA, Van Seventer EE, Shukla SA, Yizhak K, Ray JP, Rosebrock D, Livitz D, Adalsteinsson V, Getz G, Duncan LM, Li B, Corcoran RB, Lawrence DP, Stemmer-Rachamimov A, Boland GM, Landau DA, Flaherty KT, Sullivan RJ, Hacohen N. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017 10 26; 8(1):1136. PMID: 29070816.
    Citations: 359     Fields:    Translation:HumansAnimals
  67. Parikh AR, Corcoran RB. Fast-TRKing Drug Development for Rare Molecular Targets. Cancer Discov. 2017 09; 7(9):934-936. PMID: 28864638.
    Citations: 3     Fields:    Translation:Humans
  68. Parikh A, Goyal L, Hazar-Rethinam M, Siravegna G, Blaszkowsky L, Russo M, Van Seventer E, Nadres B, Shahzade H, Clark J, Allen J, John IA, Ryan DP, Murphy J, Bardelli A, Zhu A, Hong T, Corcoran R. Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients. Ann Oncol. 2017 Jun; 28 Suppl 3:iii137. PMID: 32135760.
    Citations:    
  69. Piotrowska Z, Stirling K, Heist R, Campo M, Rizzo C, Digumarthy SR, Lanuti M, Fintelmann FJ, Lennes I, Farago A, Gainor J, Azzoli CG, Temel J, Mino-Kenudson M, Dias-Santagata D, Corcoran R, Shaw A, Engelman JA, Hata A, Sequist LV. Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy. Int J Radiat Oncol Biol Phys. 2017 May 01; 98(1):220. PMID: 28586967.
    Citations:    Fields:    
  70. Ahronian LG, Corcoran RB. Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy. Genome Med. 2017 04 21; 9(1):37. PMID: 28431544.
    Citations: 19     Fields:    Translation:Humans
  71. Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, Van Seventer EE, Gurski JM, Baltschukat S, Schacher-Engstler B, Barys L, Stamm C, Furet P, Ryan DP, Stone JR, Iafrate AJ, Getz G, Porta DG, Tiedt R, Bardelli A, Juric D, Corcoran RB, Bardeesy N, Zhu AX. Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov. 2017 03; 7(3):252-263. PMID: 28034880; PMCID: PMC5433349.
    Citations: 172     Fields:    Translation:Humans
  72. Manchado E, Weissmueller S, Morris JP, Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT, Gainor JF, Corcoran RB, Engelman JA, Rudin CM, Rosen N, Lowe SW. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016 06 30; 534(7609):647-51. PMID: 27338794; PMCID: PMC4939262.
    Citations: 192     Fields:    Translation:HumansAnimalsCells
  73. Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F. Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. Cancer Res. 2016 08 01; 76(15):4504-15. PMID: 27312529; PMCID: PMC4970882.
    Citations: 49     Fields:    Translation:HumansCells
  74. Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta E, Truini M, Jessop NA, Robinson HE, Hong TS, Mino-Kenudson M, Di Nicolantonio F, Thabet A, Sartore-Bianchi A, Siena S, Iafrate AJ, Bardelli A, Corcoran RB. Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discov. 2016 Feb; 6(2):147-153. PMID: 26644315.
    Citations: 175     Fields:    Translation:HumansCells
  75. Corcoran RB. New therapeutic strategies for BRAF mutant colorectal cancers. J Gastrointest Oncol. 2015 Dec; 6(6):650-9. PMID: 26697198; PMCID: PMC4671849.
    Citations: 15     
  76. Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Borger DR, Godfrey JT, Jessop NA, Clark JW, Blaszkowsky LS, Ryan DP, Lennerz JK, Iafrate AJ, Bardelli A, Hong TS, Corcoran RB. Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. Cancer Discov. 2015 12; 5(12):1271-81. PMID: 26432108.
    Citations: 76     Fields:    Translation:Humans
  77. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015 Dec 01; 33(34):4023-31. PMID: 26392102; PMCID: PMC4669588.
    Citations: 206     Fields:    Translation:HumansAnimalsCTClinical Trials
  78. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015 Jul; 21(7):827. PMID: 26151329.
    Citations: 107     Fields:    
  79. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015 Jul; 21(7):795-801. PMID: 26030179; PMCID: PMC4868598.
    Citations: 355     Fields:    Translation:HumansCells
  80. Ahronian LG, Corcoran RB. Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations. Mol Cell Oncol. 2016 Jan; 3(1):e1048405. PMID: 27308562; PMCID: PMC4845183.
    Citations: 7     
  81. Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M, Getz G, Dias-Santagata D, Iafrate AJ, Engelman JA, Garraway LA, Corcoran RB. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov. 2015 Apr; 5(4):358-67. PMID: 25673644.
    Citations: 143     Fields:    Translation:HumansCells
  82. Atreya CE, Corcoran RB, Kopetz S. Expanded RAS: refining the patient population. J Clin Oncol. 2015 Mar 01; 33(7):682-5. PMID: 25584005; PMCID: PMC4334773.
    Citations: 25     Fields:    Translation:Humans
  83. Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R, Benes CH, Engelman J, Bardeesy N. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res. 2015 Jan 15; 21(2):396-404. PMID: 25348516.
    Citations: 67     Fields:    Translation:HumansAnimalsCells
  84. Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P, Godfrey JT, Qian ZR, Page AN, Maciag K, Chan EM, Silkworth W, Labowsky MT, Rozhansky L, Mesirov JP, Gillanders WE, Ogino S, Hacohen N, Gaudet S, Eck MJ, Engelman JA, Corcoran RB, Wong KK, Hahn WC, Barbie DA. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014 Apr; 4(4):452-65. PMID: 24444711; PMCID: PMC3980023.
    Citations: 108     Fields:    Translation:HumansAnimalsCells
  85. Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, Corcoran RB, Rivera MN, Ramaswamy S, Hung KE, Benes CH, Engelman JA. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov. 2014 Jan; 4(1):42-52. PMID: 24163374; PMCID: PMC3973435.
    Citations: 71     Fields:    Translation:HumansAnimalsCells
  86. Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med. 2013 Jul 31; 5(196):196ra98. PMID: 23903755; PMCID: PMC3867020.
    Citations: 86     Fields:    Translation:HumansAnimalsCells
  87. Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, Song Y, Lifshits E, Hung KE, Shioda T, Dias-Santagata D, Singh A, Settleman J, Benes CH, Mino-Kenudson M, Wong KK, Engelman JA. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell. 2013 Jan 14; 23(1):121-8. PMID: 23245996.
    Citations: 200     Fields:    Translation:HumansAnimals
  88. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M, Engelman JA. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012 Mar; 2(3):227-35. PMID: 22448344.
    Citations: 453     Fields:    Translation:HumansAnimalsCells
  89. Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest. 2011 Nov; 121(11):4311-21. PMID: 21985784; PMCID: PMC3204842.
    Citations: 118     Fields:    Translation:HumansAnimalsCells
  90. Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, Gómez HL, Baselga J, Arteaga CL, Rivera MN, Dias-Santagata D, Jain RK, Engelman JA. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 2011 Sep; 1(4):352-65. PMID: 22145099.
    Citations: 167     Fields:    Translation:HumansAnimalsCells
  91. Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA, Bardeesy N. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011 Jul 15; 71(14):5020-9. PMID: 21586612; PMCID: PMC3693754.
    Citations: 225     Fields:    Translation:HumansAnimalsCells
  92. Corcoran RB, Settleman J, Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget. 2011 Apr; 2(4):336-46. PMID: 21505228.
    Citations: 64     Fields:    Translation:HumansAnimals
  93. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal. 2010 Nov 23; 3(149):ra84. PMID: 21098728.
    Citations: 155     Fields:    Translation:HumansCells
  94. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010 Feb 20; 28(6):1075-83. PMID: 20085938.
    Citations: 524     Fields:    Translation:HumansAnimals
  95. Rohatgi R, Milenkovic L, Corcoran RB, Scott MP. Hedgehog signal transduction by Smoothened: pharmacologic evidence for a 2-step activation process. Proc Natl Acad Sci U S A. 2009 Mar 03; 106(9):3196-201. PMID: 19218434; PMCID: PMC2642660.
    Citations: 151     Fields:    Translation:AnimalsCells
  96. Corcoran RB, Bachar Raveh T, Barakat MT, Lee EY, Scott MP. Insulin-like growth factor 2 is required for progression to advanced medulloblastoma in patched1 heterozygous mice. Cancer Res. 2008 Nov 01; 68(21):8788-95. PMID: 18974121; PMCID: PMC2597356.
    Citations: 35     Fields:    Translation:AnimalsCells
  97. Corcoran RB, Scott MP. Oxysterols stimulate Sonic hedgehog signal transduction and proliferation of medulloblastoma cells. Proc Natl Acad Sci U S A. 2006 May 30; 103(22):8408-13. PMID: 16707575; PMCID: PMC1462959.
    Citations: 142     Fields:    Translation:AnimalsCells
  98. De Brún C, Howell F, Bedford D, Corcoran R, Kelly A. Outpatient experiences in acute hospitals. Ir J Med Sci. 2002 Apr-Jun; 171(2):89-93. PMID: 12173897.
    Citations: 3     Fields:    Translation:Humans
  99. Corcoran RB, Scott MP. A mouse model for medulloblastoma and basal cell nevus syndrome. J Neurooncol. 2001 Jul; 53(3):307-18. PMID: 11718263.
    Citations: 39     Fields:    Translation:Animals
  100. O'Connell T, Browne C, Corcoran R, Howell F. Quality of life following total hip replacement. Ir Med J. 2000 Jun; 93(4):108-10. PMID: 11037568.
    Citations: 2     Fields:    Translation:Humans
  101. Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ. WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev. 2000 Mar 01; 14(5):585-95. PMID: 10716946.
    Citations: 133     Fields:    Translation:AnimalsCells
  102. Bedford D, Howell F, Corcoran R. The provision of influenza vaccine to patients over 65 years by general practitioners. Ir Med J. 1997 Oct; 90(6):231-2. PMID: 9611925.
    Citations: 3     Fields:    Translation:HumansPHPublic Health
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Corcoran's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (339)
Explore
_
Co-Authors (203)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.